Contents

Search

Prevent Recurrence of Osteoporotic Fracture (PROOF) Study

Study characteristics: - randomized, controlled, double blind trial of inhaled (nasal) salmon calcitonin 100, 200 or 400 IU - all received 1000 mg of calcium + 400 IU vitamin D QD - 1255 postmenopausal women with established osteoporosis - 1-5 vertebral fractures - bone mineral density T scores < -2 Results: - 200 IU: 33% reduction in vertebral fractures - 100 or 400 IU: a) 15% (non significant) reduction in vertebral fractures b) No significant effect on bone mineral density or vertebrae or hip

Related

bone mineral density (BMD) calcitonin; contains: katacalcin; calcitonin carboxyl-terminal peptide; CCP; PDN-21 (CALC, CALC1) osteoporosis vitamin D

General

clinical trial

References

  1. Greenwood G. In: Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 12-15, 2001
  2. Chestnut CH et al, Am J Med 109:267, 2000